Brief: Karuna Therapeutics Announces Positive Results From Phase 3 EMERGENT-2 Trial Of KarXT In Schizophrenia

Karuna Therapeutics

08/08/2022 11:37

Aug 8 (Reuters) - Karuna Therapeutics Inc  KRTX.O :
    * KARUNA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE
3
EMERGENT-2 TRIAL OF KARXT IN SCHIZOPHRENIA
    * KARUNA THERAPEUTICS INC - TRIAL ALSO MET KEY SECONDARY
ENDPOINTS
    * KARUNA THERAPEUTICS INC - TRIAL MET PRIMARY ENDPOINT
    * KARUNA THERAPEUTICS INC - TRIAL MET PRIMARY ENDPOINT, WITH
KARXT
DEMONSTRATING A STATISTICALLY SIGNIFICANT 9.6-POINT REDUCTION IN
PANSS TOTAL SCORE
    * KARUNA THERAPEUTICS INC - KARXT WAS GENERALLY WELL
TOLERATED,
WITH A SIDE EFFECT PROFILE SUBSTANTIALLY CONSISTENT WITH PRIOR
TRIALS OF KARXT IN SCHIZOPHRENIA
    * KARUNA THERAPEUTICS INC - PLANS TO SUBMIT A NEW DRUG
APPLICATION
(NDA) WITH U.S. FOOD & DRUG ADMINISTRATION (FDA) IN MID-2023
    * KARUNA THERAPEUTICS INC - ADDITIONAL ANALYSIS OF DATA FROM
PHASE
3 EMERGENT-2 TRIAL IS ONGOING
    * KARUNA THERAPEUTICS INC - TOPLINE DATA FROM PHASE 3
EMERGENT-3
TRIAL ARE EXPECTED IN Q1 OF 2023

Source text for Eikon:  ID:nBw8YhpY8a 
Further company coverage:  KRTX.O